Intech Investment Management LLC raised its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 64.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 92,300 shares of the medical equipment provider's stock after purchasing an additional 36,104 shares during the quarter. Intech Investment Management LLC's holdings in Hologic were worth $6,654,000 as of its most recent SEC filing.
Several other institutional investors have also recently made changes to their positions in HOLX. General Partner Inc. purchased a new stake in Hologic during the fourth quarter valued at approximately $26,000. Venturi Wealth Management LLC grew its holdings in Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after purchasing an additional 261 shares during the period. First Horizon Advisors Inc. grew its stake in shares of Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock valued at $39,000 after acquiring an additional 134 shares during the period. EverSource Wealth Advisors LLC boosted its position in shares of Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 260 shares during the period. Finally, Smartleaf Asset Management LLC boosted its position in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 159 shares during the period. Institutional investors own 94.73% of the company's stock.
Hologic Trading Up 0.8 %
HOLX stock traded up $0.46 during trading on Friday, hitting $61.47. The company had a trading volume of 7,416,503 shares, compared to its average volume of 1,750,784. The firm has a market capitalization of $13.79 billion, a P/E ratio of 19.39, a PEG ratio of 2.14 and a beta of 0.97. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 52-week low of $60.34 and a 52-week high of $84.67. The company has a 50 day simple moving average of $66.06 and a 200-day simple moving average of $73.99.
Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on HOLX. Raymond James reiterated an "outperform" rating and issued a $90.00 price target (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Stephens restated an "overweight" rating and set a $84.00 target price on shares of Hologic in a research report on Thursday, February 6th. Morgan Stanley cut their price objective on Hologic from $84.00 to $82.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. Argus lowered Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Finally, Leerink Partnrs downgraded shares of Hologic from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $84.62.
Get Our Latest Stock Report on Hologic
About Hologic
(
Free Report)
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Further Reading
Before you consider Hologic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.
While Hologic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
